Summary of Key Points
In 2026, the anti-corruption efforts in the pharmaceutical industry have focused on new tactics within the pharmaceutical purchasing and sales sector: unscrupulous companies are using "pseudo-research," "pseudo-academic conferences," and "pseudo-donations" as fronts for profit transfer. Other issues include fraudulent invoicing, abnormally low prices in government procurement, and inflated drug prices. Multiple departments have taken joint action to tighten oversight by strengthening data regulation, conducting targeted investigations into tax-related violations, cracking down on maliciously low bids, and promoting volume-based purchasing initiatives, all with the aim of reducing the industry's gray areas and making pharmaceutical transactions more transparent.
Detailed Analysis
1. "Pseudo-research" as a New Mask for Cash-based Sales? Regulation Must Expose It
The traditional practice of directly offering bribes to doctors has been effectively curbed. Now, pharmaceutical companies have adopted a more sophisticated approach: they use third parties (such as medical technology firms) to conduct "researcher-initiated trials (IIT)" or "real-world studies (RWE)," and offer doctors "observation fees" or "research funding," with the real purpose of encouraging them to prescribe their products.
For example, during a surprise inspection by healthcare insurance authorities, it was discovered that the sales volume of a certain drug increased dramatically from 2 million to 8 million units, with most of the purchases covered by health insurance. Meanwhile, one-quarter of the hospital's approved drug research projects involved this particular drug. The studies either portrayed the drug as a versatile remedy or as a lifesaver for cancers with no available treatments, clearly using the guise of research to promote sales.
Regulatory Response: Strengthening the traceability of medical data throughout its entire cycle, strictly prohibiting data breaches and resale, and blocking any attempts to profit from research data at the source.
2. Pseudo-academic Activities and Donations Cannot Hide the Truth
In addition to pseudo-research, "pseudo-academic conferences" and "pseudo-donations" are also common channels for profit transfer:
- For doctors: Some doctors accept benefits from pharmaceutical companies in exchange for participating in academic activities or practice multiple locations illegally to earn extra money.
- For associations: Certain industry associations help companies indirectly distribute funds by lending their credentials, organizing conferences, or accepting donations.
Regulatory Response: Focusing on addressing unethical behavior among doctors and regulating associations that use their influence for personal gain, ensuring that "academic" and "charitable" activities remain true to their purpose.
3. Targeted Actions Against Tax-related Violations: Fraudulent Invoicing Leads to Consequences
Where does the money for cash-based sales come from? Often, it results from fraudulent invoicing and concealment of revenue by pharmaceutical companies. For instance, in the medical device industry, common practices include manipulating or altering invoices (changing amounts and content) and issuing false value-added tax (VAT) invoices to siphon off funds.
Regulatory Response: Not only do companies that issue fraudulent invoices face consequences, but so do the organizations that accept them (such as hospitals). There is also enhanced monitoring of the entire invoice chain and credit evaluations; both parties will be held accountable for any violations.
4. Abnormally Low Prices in Government Procurement: Malicious Bidding Practices Must Be Investigated
In the bidding for medical equipment and high-value consumables, some companies deliberately submit extremely low bids to win contracts. Once awarded, they may cut corners (using substandard materials) or later raise prices under various pretexts. Additionally, procurement officials (hospitals or departments) may interfere with the process by splitting projects to avoid competition, setting specific criteria to favor certain companies, or conducting secret bidding arrangements.
Regulatory Response: Strictly enforcing government procurement laws, focusing on high-value consumables and equipment sectors, and cracking down on practices such as leasing licenses and commercial bribery to address the underlying issues of quality and corruption associated with abnormally low prices.
5. Reducing Inflated Drug Prices: Expanding Volume-based Purchasing and Direct Medical Insurance Settlements
High drug prices are largely due to inflated costs. This year's strategies include:
- Expanding volume-based purchasing: More drugs and consumables will be included in centralized procurement to drive down prices through bulk buying.
- Direct medical insurance settlements: Health insurance will pay directly to pharmaceutical companies, eliminating middlemen (such as distributors) who add extra costs.
- Cracking down on price-related violations: Investigating practices such as failing to list prices accurately, price fraud, and collusive price hikes.
- Addressing payment delays: Ensuring that pharmaceutical companies receive their payments promptly to reduce financial pressure.
These measures will ultimately make drug prices more affordable for consumers.
Conclusion
The anti-corruption efforts in the pharmaceutical industry in 2026 are not a temporary initiative but a targeted response to new unethical practices within the sector. By addressing issues ranging from research and academia to invoicing and bidding, as well as pricing and payment processes, the goal is to eliminate loopholes throughout the entire supply chain. For consumers, this will likely result in cheaper and more reliable medication; for pharmaceutical companies, only genuine innovation and quality will be key to survival—unethical tactics will no longer be effective.